You are here
Home > Top Stories > WHO rejects Serum Institute’s proposal in search of extension of Covishield’s shelf life from 6 to 9 months

WHO rejects Serum Institute’s proposal in search of extension of Covishield’s shelf life from 6 to 9 months


Image Source : FILE/PTI

Advertisement

WHO rejects Serum Institute’s proposal in search of extension of Covishield’s shelf life from 6 to 9 months

The WHO has rejected Serum Institute of India’s proposal in search of extension of the shelf lifetime of Oxford-AstraZeneca COVID-19 vaccine, Covishield, from six to 9 months, citing inadequate information, sources mentioned.

The WHO has additionally sought a gathering with Drugs Controller General of India (DCGI) to debate the matter, they mentioned.

The transfer comes at the same time as India’s drug regulator has prolonged Covishield’s shelf life from six to 9 months from its manufacturing date.

In a current communique to Pune-based Serum Institute of India (SII), the WHO has additionally requested the agency to formulate the doses with sufficient titer and/or implement the next specification at launch in order that the minimal specification of  ≥  2.5 x 108 ifu/dose is fulfilled all through the shelf life.

  
Shelf life is the size of time for which an merchandise stays match to be used.

The DCGI in a letter to SII in February mentioned it has no objection in respect of ‘extension of shelf lifetime of Covishield vaccine’ in multi-dose glass vial (10 dose-5ml) from six months to 9 months.

“You are permitted to apply the shelf life of nine months to unlabelled vials available on hand, subject to the condition that the details of such stock, batch-wise, shall be submitted to this office and Central Drugs Laboratory, Kasauli,” DCGI Dr V G Somani had mentioned within the letter.

The DCGI’s determination will assist well being authorities in lowering vaccine wastage.
 
According to an replace by the UK drug regulator dated February 22, the shelf-life of the AstraZeneca COVID-19 vaccine is six months.

Meanwhile, issues have been raised in regards to the  vaccine because the European Union’s well being company concluded a “possible link” between the vaccine and uncommon blood clots however  confused that the advantages of the vaccine to guard towards COVID-19 proceed to outweigh the dangers.

The UK’s medicines regulator on Wednesday mentioned that under-30s within the nation can be provided a substitute for the Oxford-AstraZeneca vaccine attributable to “evolving evidence” linking it to uncommon blood clots.
 
Developed by Oxford University and Swedish-British pharma main AstraZeneca, Covishield is being manufactured by SII.

READ MORE: AstraZeneca authorized discover to Serum Institute over delays

Latest World News



Similar Articles

Leave a Reply

Top